Key Figures Q1 2022
|
SEK m, unless otherwise stated |
2022 Jan-Mar |
2021 Jan-Mar |
% Change |
2021 Jan-Dec |
|
Net revenues |
159.4 |
132.3 |
20.5% |
565.0 |
|
Cost of goods sold |
-27.5 |
-19.2 |
43.8% |
-78.9 |
|
Operating expenses |
-145.1 |
-149.9 |
-3.2% |
-700.2 |
|
EBIT |
-13.2 |
-36.8 |
64.2% |
-214.1 |
|
EBIT margin, % |
-8.3% |
-27.8% |
19.6% |
-37.9% |
|
EBITDA |
2.8 |
-23,9 |
111.7% |
-161.0 |
|
Earnings per share, before dilution, SEK |
-0.69 |
-0.92 |
25.0% |
-6.51 |
|
Earnings per share, after dilution, SEK |
-0.69 |
-0.92 |
25.0% |
-6.51 |
|
Cash flow from operating activities |
-61.6 |
-47.8 |
-28.9% |
-229.0 |
|
Cash and cash equivalents |
437.8 |
725.5 |
-39.7% |
504.1 |
Net revenues and EBIT per segment Q1 2022
|
SEK m |
Net Revenues |
EBIT |
||||
|
2022 Jan-Mar |
2021 Jan-Mar |
2021 Jan-Dec |
2022 Jan-Mar |
2021 Jan-Mar |
2021 Jan-Dec |
|
|
ZUBSOLV® US |
139.1 |
126.8 |
522.7 |
- |
- |
- |
|
US Pharma – total |
139.1 |
126.8 |
522.7 |
84.0 |
66.1 |
278.2 |
|
Digital Therapeutics (DTx) product sales |
0.2 |
0,2 |
1.1 |
- |
- |
- |
|
Digital Therapeutics (DTx) – total |
0.2 |
0,2 |
1.1 |
-43.4 |
-58.7 |
-249.7 |
|
Abstral® royalties |
12.4 |
2.7 |
32.1 |
- |
- |
- |
|
Edluar® royalties |
3.2 |
2.6 |
9.1 |
- |
- |
- |
|
ZUBSOLV® - ex US |
4.6 |
- |
- |
- |
- |
- |
|
HQ & Pipeline segment - total |
20.1 |
5.3 |
41.2 |
-53.7 |
-44.2 |
-242.6 |
|
Total |
159.4 |
132.3 |
565.0 |
-13.2 |
-36.8 |
-214.1 |
Cash flow Q1 2022
|
SEK m |
2022 Jan-Mar |
2021 Jan-Mar |
2021 Jan-Dec |
|
Cash flow from operating activities |
-61.6 |
-47.8 |
-299.0 |
|
Investment activities |
-5.6 |
-16.2 |
-52.9 |
|
Financing activities |
-5.3 |
261.7 |
250.6 |
|
Cash flow (excl exchange rate differences) |
-72.5 |
197.7 |
-31,2 |
|
Liquid funds |
437.8 |
725.5 |
504.1 |